Jun 22, 2020
Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology
Jun 18, 2020
ArcherDX Enters Collaboration with Bristol Myers Squibb to Apply Personalized Cancer Monitoring (PCM(TM)) to Clinical Research
May 26, 2020
ArcherDX Announces Strategic Collaboration with AstraZeneca to Develop Personalized Cancer Monitoring (PCM) Assays for Minimal Residual Disease (MRD)
May 19, 2020
ArcherDX Receives Breakthrough Device Designation to Detect NTRK Gene Fusions
May 07, 2020
ArcherDX Appoints Jason Ryan to Board of Directors
Apr 28, 2020
ArcherDX and UCL Present New Minimal Residual Disease Surveillance Data from their Collaboration at 2020 AACR Virtual Annual Meeting
Mar 25, 2020
ArcherDX Receives Approval for Archer®MET Companion Diagnostic for TEPMETKO® (Tepotinib) in Advanced Non-Small Cell Lung Cancer in Japan
Jan 14, 2020
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
Jan 10, 2020
ArcherDX and Illumina Partner for Future to Co-Market Portfolio of Planned In-Vitro Diagnostic (IVD) Tests
Jan 07, 2020
ArcherDX Appoints Mark Massaro Chief Financial Officer
Dec 17, 2019
ArcherDX Announces Close of $55 Million Series C Financing
Jul 08, 2019
ArcherDX and Ayala Pharmaceuticals Announce Strategic Companion Diagnostic Collaboration
May 29, 2019
ArcherDX Announces the Appointment of Steven J. Kafka, Ph.D. as Executive Chairman of the Board of Directors
Mar 28, 2019
ArcherDX announces collaboration with University College London to Investigate the Novel Use of Cell-Free Circulating Tumor DNA to Detect Disease Recurrence in Lung Cancer Patients
Feb 12, 2019
ArcherDX Announces Broad-Based Strategic Collaboration with Genosity
Jan 08, 2019
ArcherDX's Companion Diagnostic Assay for both Liquid Biopsy and Tissue Specimens Granted Breakthrough Device Designation by U.S. Food and Drug Administration
Sep 05, 2018
ArcherDX, Inc. Names Former Foundation Medicine Executive Steven Kafka, Ph.D. to its Board of Directors
Aug 28, 2018
ArcherDX, Inc. Appoints Marvin H. Caruthers, Ph.D., to its Board of Directors
Mar 20, 2018
ArcherDX Closes $35 Million Series A Financing